Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 82.52M shares rose 8.6% year over year, ahead of the -1.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 31.1% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8.6% holds above the trailing-twelve-month pace of -1.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 76.96M USD
- Year-over-year change
- +1.5%
- 4-year CAGR
- +12.8%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.96M | +1.5% |
| FY2024 | 2024-12-31 | 75.81M | +25.6% |
| FY2023 | 2023-12-31 | 60.36M | +27.4% |
| FY2022 | 2022-12-31 | 47.37M | -0.5% |
| FY2021 | 2021-12-31 | 47.6M | — |
Weighted Avg Shares vs competitors
How PRLD compares with its peers on the latest reported figures
- PRLD's LTM Mar 2026 weighted avg shares of 74.4M shares is the 4th highest of the 11 companies compared; the peer median is 53.52M shares.
- Its year-over-year change of -1.9% is the lowest of 11, against a peer median of +16.4%.
- Over three fiscal years its annual growth of +17.6% compares with a peer median of +21.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | 186.8M | +259.4% | +65.2% | |
| LTM Mar 2026 | 158.02M | +71.7% | +50.6% | |
| LTM Mar 2026 | 94.18M | +3.6% | +15.4% | |
| LTM Mar 2026 | 74.4M | -1.9% | +17.6% | |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 62.52M | +2.9% | +23.4% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | 44.51M | +24.9% | +27.5% |
| LTM Mar 2026 | 40.92M | +29.8% | +18.6% | |
| LTM Mar 2026 | 38.39M | +2.6% | +14.7% | |
| LTM Mar 2026 | 21.37M | +0.6% | +1.2% | |
| LTM Mar 2026 | 15.86M | +130.2% | +599.3% | |
| Peer median (excluding PRLD) | 53.52M | +16.4% | +21.0% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.